Good morning, and welcome to the Plexus Corp. Conference Call regarding the Fiscal First Quarter 2020 Earnings Announcement. My name is John, and I'll be your operator for today's call. Please note that this conference is being recorded. And I would now like to turn the call over to Ms. Heather Beresford, Plexus' Senior Director of Communications and Investor Relations. Heather?

Good morning, and thank you for joining us today. Some of the statements made and information provided during our call today will be forward-looking statements as they will not be limited to historical facts. The words believe, expect, intend, plan, anticipate and similar terms often identify forward-looking statements. Forward-looking statements are not guarantees since there are inherent difficulties in predicting future results, and actual results could differ materially from those expressed or implied in the forward-looking statements. For a list of factors that could cause actual results to differ materially from those discussed, please refer to the company's periodic SEC filings, particularly the risk factors in our Form 10-K filing for the fiscal year ended September 28, 2019, and the safe harbor and fair disclosure statement in yesterday's press release. Plexus provides non-GAAP supplemental information such as ROIC, economic return and free cash flow because those measures are used for internal management goals and decision-making and because they provide additional insight into financial performance. In addition, management uses these and other non-GAAP measures such as adjusted operating income, adjusted operating margin, adjusted net income and adjusted earnings per share to provide a better understanding of core performance for purposes of period-to-period comparison. For a full reconciliation of non-GAAP supplemental information, please refer to yesterday's press release and our periodic SEC filings. We encourage participants on the call this morning to access the live webcast and supporting materials at Plexus' website at www.plexus.com, clicking on Investors at the top of that page. Joining me today are Todd Kelsey, President and Chief Executive Officer; Steve Frisch, Executive Vice President and Chief Operating Officer; and Pat Jermain, Executive Vice President and Chief Financial Officer. Consistent with prior earnings calls, Todd will provide summary comments before turning the call over to Steve and Pat for further details. Let me now turn the call over to Todd Kelsey. Todd?

Thank you, Heather, and good morning, everyone. Please begin with our fiscal first quarter results on Slide 3. After the close of the market yesterday evening, we reported results for our fiscal first quarter of 2020. We achieved record quarterly revenue of $852 million, which exceeded the top end of our guidance range of $780 million to $820 million. This revenue represents 11% growth over the comparable period in fiscal 2019 and 5% growth sequentially. Our Healthcare/Life Sciences sector exceeded our expectations coming into the quarter as our team responded to increased demand from several customers. In addition, our Industrial/Commercial sector produced exceptional results as we capitalized on further strengthening in the semiconductor capital equipment market and broad improvements in demand throughout the remainder of the sector. We delivered GAAP EPS of $1.03, including $0.17 of stock-based compensation expense and non-GAAP EPS of $1, both exceeded our guidance range, which was $0.87 to $0.97. The non-GAAP result excluded a net $0.03 benefit due to special tax items. Our global teams continue to prioritize operational excellence and through that focus, delivered fiscal first quarter operating margin of 4.7% at the midpoint of our guidance range and within our target range of 4.7% to 5%. Please advance to Slide 4. Next, I will discuss additional accomplishments within the fiscal first quarter of 2020. I will start with items associated with the balance sheet. We continue to make progress on our working capital initiatives in the fiscal first quarter. We ended the quarter at 87 days of inventory, representing an 18-day improvement from the first quarter of fiscal 2019. Our inventory performance, coupled with improved receivables days and payables days, led to a cash conversion cycle of 71 days. Our cash cycle is down 18 days over the past 2 quarters. The end result was another exceptional quarter of free cash flow. We delivered $61 million of free cash flow in the fiscal first quarter. This follows a result of $92 million in the fiscal fourth quarter of 2019. We created meaningful shareholder value and delivered return on invested capital of 14.7%. This result represents an economic return of 590 basis points above our weighted average cost of capital of 8.8% and exceeds our target of 500 basis points. Next, I will highlight accomplishments related to our revenue growth. Despite having been impacted by award timing around the holidays, our teams delivered $167 million of manufacturing wins within the fiscal first quarter. Our Healthcare/Life Sciences team had another particularly strong quarter with $85 million in wins, predominantly with existing customers due to our capabilities and proficiency at delivering exceptional quality products. The continued strong wins performance positions our Healthcare/Life Sciences sector for an excellent fiscal 2021. Our wins momentum, which we define as trailing 4-quarter wins, divided by trailing 4-quarter revenue, remains above our target of 25%. This level is sufficient to maintain solid growth within our differentiated markets. In addition, our teams reported a funnel of qualified manufacturing opportunities of $2.5 billion, which is a reflection of the diligence and strategic focus of our global market sector teams. We expect to leverage this funnel to deliver a strong wins result in the fiscal second quarter. Our Industrial/Commercial sector is exploiting portfolio diversification, program ramps, and strengthening within the semiconductor capital equipment space to drive outstanding growth. Our fiscal first quarter revenue was up 42% from the comparable period in fiscal 2019. Our Aerospace and Defense sector continues to show signs of another exceptional growth year. Our fiscal first quarter results represented 41% year-over-year revenue growth. Our focus on zero defects and perfect delivery resonates with customers in these highly complex markets. Please advance to Slide 5. Our portfolio continues to differentiate Plexus from our peers as we strengthen our leadership in highly complex products and demanding regulatory environments. Within the fiscal first quarter, 93% of our revenue was generated from the combined Healthcare/Life Sciences, Industrial/Commercial and Aerospace and Defense market sectors. This position has increased from 79% just 3 years ago, during a period of significant revenue growth. Our focus in these complex markets provides advantages in operational efficiency and results in more consistent, reliable performance for our customers. Advancing to our guidance for the fiscal second quarter of 2020 on Slide 6. We expect revenue to moderate in the fiscal second quarter as we believe some of the fiscal first quarter strength is impacting current quarter demand, particularly in our Healthcare/Life Sciences sector. We expect continued strength in our Industrial/Commercial and Aerospace and Defense business, with revenue relatively flat within these sectors as compared to the strong results of the previous quarter. As a result of these factors, we are guiding revenue in the range of $790 million to $830 million. Our operating margin is being impacted by seasonal payroll costs, which we estimate at about 50 basis points and the pause of two substantial programs in our engineering organization. As such, we are guiding operating margin in the range of 4.0% to 4.5%. We anticipate revenue and operating margin at these levels will lead to GAAP EPS in the range of $0.80 to $0.90, including $0.21 of stock-based compensation expense and excluding any nonrecurring charges. We are proactively responding to the engineering program pauses by strategically repositioning our Boulder Design Center to co-locate with our existing manufacturing facility in Boise, Idaho. This opportunity will allow for the creation of an Aerospace and Defense Center of Excellence. This combination of engineering and manufacturing services will provide the synergies and cost advantages of a campus environment, while delivering a compelling service offering for our customers in the Aerospace and Defense sector. Our Boise manufacturing facility is rapidly growing its Aerospace and Defense business and is also home to our Microelectronics Center of Excellence. Please advance to Slide 7 for a few thoughts regarding fiscal 2020. Our outlook for fiscal 2020 remains generally unchanged from previous expectations. We anticipate sequentially increasing revenue during the second half of the fiscal year as we benefit from our recent wins performance, largely stable end markets, and improving semiconductor capital equipment demand resulting in solid revenue growth for the fiscal year. We are enthused with the outlook for our Aerospace and Defense and Industrial/Commercial sectors where we expect robust growth. In addition, we anticipate fiscal 2020 revenue in the combined Healthcare/Life Sciences, Industrial/Commercial and Aerospace and Defense sectors to exceed 90% of our portfolio, consistent with our fiscal first quarter results. These sectors have programs with longer life cycles, in many cases, 10 years or more. We have achieved compounded annual growth rates in the teens within these markets. Our goal is to maintain these growth rates as we move beyond fiscal 2020. Coupling the anticipated fiscal 2020 growth with our comprehensive service offerings, focused on operational excellence, aligned cost structure and talented workforce committed to delighting our customers, we expect solid operating performance with return to operating margins within our target range of 4.7% to 5% in the second half of the year. This level of performance would enable robust EPS expansion for the full fiscal year. I will now turn the call over to Steve for additional analysis of the performance of our market sectors and operations. Steve?

Thank you, Todd. Good morning. Please advance to Slide 8 for a review of our performance by market sector for the fiscal first quarter of 2020, as well as our expectations for the sectors for the second fiscal quarter of 2020. Our Healthcare/Life Sciences revenue was flat in the fiscal first quarter. The result easily surpassed our expectations of a mid-single-digit decline. Our customers' forecast did not show seasonal strength as we entered the quarter; however, 15 of our top 20 customers in the sector increased forecast within the quarter to meet robust calendar year-end demand. The strong calendar year-end shipments are impacting our fiscal second quarter projections. We expect approximately a 10% decline for our Healthcare/Life Sciences sector in the fiscal second quarter. We believe this demand swing is a short-term correction, and the sector will rebound in the fiscal third quarter. Revenue in our Industrial/Commercial sector increased 17% for the fiscal first quarter. The result was significantly better than our expectations of a low single-digit increase. Although the largest revenue increases were led by our semiconductor capital equipment customers, greater demand from 11 of the top 12 customers and the remaining subsectors contributed to the strong growth. As we look at the fiscal second quarter, we expect that the semiconductor capital equipment subsector will maintain the increased level of demand; however, we see a modest pullback in some of the other subsectors. The net result is that we are anticipating revenue to be flat for our Industrial/Commercial sector in the fiscal second quarter. We are in close communication with several of our semiconductor capital equipment customers as there are indications that we may see additional upside to our current forecast for calendar 2020. The obvious questions we're trying to answer are when and how much? Our Aerospace and Defense sector was down 1% in the fiscal first quarter. The result was slightly lower than our expectations of a moderate increase; slightly slower ramps on two programs were the main reason for the lower revenue. Looking at the fiscal second quarter, we expect growth with new program ramps to be offset by modest softness with three aerospace customers. As a result, we are expecting flat revenue for our Aerospace and Defense sector in the fiscal second quarter. We anticipate that the new program ramps will be largely complete within the quarter, and that they will provide meaningful growth for the sector in the fiscal third quarter. Our Communications sector declined 5% in the fiscal first quarter, a result that was below our expectations of flat revenue. Weaker demand from four of our top five customers was the cause for the decline. As we look towards the fiscal second quarter, we see continuing softness from customers in the sector. As a result, we are expecting a mid-teens decline in our Communications sector for the fiscal second quarter. We expect to gain more visibility regarding the calendar 2020 outlook from our Communications customers as we progress through this quarter. Please advance to Slide 9 for an overview of the wins performance of the fiscal first quarter. We won 30 new manufacturing programs that we expect to generate $167 million in annualized revenue when fully ramped into production. We experienced slower-than-typical decision-making during the holiday season, which had a negative impact on the wins results in the fiscal first quarter. As we look at the fiscal second quarter, our wins performance has started very strong, and we anticipate a solid result for this quarter. Our trailing four quarters of wins at almost $850 million yield a win momentum of 26%. The result is above our goal and continues to support our growth strategy. Please advance to Slide 10 for further insight into the wins results by region. The Americas region had another strong quarter of wins at $89 million in the fiscal first quarter. Our focus on the design and manufacturing of highly complex products and demanding regulatory environments continues to fuel our growth. The Americas wins in the quarter included two large robotic-assisted medical devices, and winning these programs is a clear indication that our strategy is working. The APAC region wins of $64 million are the result of diverse capabilities the team has developed. The wins vary from a small single-use medical device that weighs a few ounces to a complex test system that weighs over several hundred pounds. These wins illustrate the vast range of expertise Plexus has developed for our customers in the differentiated markets we serve. The EMEA region's wins of $14 million highlight the importance of our commitment to operational excellence in the region. Market share gains in a long-term security customer as well as the addition of a new division from a transportation customer are indicators that the dividend from our great execution is growth with our customers. Please advance to Slide 11 for further insight into the manufacturing wins performance by market sector. Our Healthcare/Life Science team had solid wins result of $85 million in the fiscal first quarter that will enable sustained growth for the sector. The robotic-assisted medical devices and the new single-use device program that I highlighted are expected to start adding meaningful revenue in fiscal 2021. The Industrial/Commercial sector produced $44 million of manufacturing wins in the fiscal first quarter. The wins included the addition of a new customer who delivers factory automation solutions through the use of robotics and artificial intelligence. Plexus' ability to demonstrate our expertise in the manufacturing of complex electromechanical assemblies was a key differentiator in securing this win. The Aerospace and Defense sector generated $17 million of new wins in the fiscal first quarter. Just as important as the size of the wins is the duration of the programs. One of the larger wins in the quarter includes a program for the C-130J airframe that we expect to build for at least the next 10 years. A highlight in the quarter was a visit by two C-130J crews to our Neenah manufacturing facility. Our teams had the opportunity to tour the planes and speak with the crews. As you can imagine, the crews appreciate our commitment to zero defects. Finally, our Communications sector wins of $21 million included a new customer who provides products that support the infrastructure and wireless connectivity and high-speed communications, including 5G applications. Please advance to Slide 12. We exited the fiscal first quarter with a robust funnel of qualified manufacturing opportunities. At $2.5 billion, we have the pipeline of new opportunities required to support continued growth. The Healthcare/Life Sciences funnel continues to be very healthy at $1.5 billion. In addition to the size of the funnel, the quality of the opportunities is strong. We expect the funnel to support robust wins performance in the fiscal second quarter and beyond. The Industrial/Commercial sector increased their funnel to $404 million while generating solid wins within the fiscal first quarter. The resource investments we made in fiscal 2019 are starting to have a positive effect on the funnel, and we expect that trend to continue in fiscal 2020. The Aerospace and Defense sector grew its funnel by 9% in the fiscal first quarter, and we see momentum in the sector continuing to build. In addition to having increased opportunities to gain market share with our customers, the pipeline of new activities that feeds the funnel is growing steadily. A few final comments. Todd highlighted our decision to relocate our Boulder Design Center to our manufacturing facility in Boise, Idaho. In one regard, it was a challenging decision, as I know some of the team will not be relocating. For those colleagues, I want to thank you for your dedication and service to Plexus during your tenure. For the colleagues who will be moving to Boise, the prospect of creating a full value stream service offering at this site, especially for our Aerospace and Defense customers, is exciting. Plexus has a strong track record of creating differentiated service offerings, and I want to thank you for your willingness and commitment to support Plexus in establishing this unique capability in Boise. I will now turn the call to Pat for an in-depth review of our financial performance. Pat?

Thank you, Steve, and good morning, everyone. Our fiscal first quarter results are summarized on Slide 13. Revenue of $852 million was above the top end of our guidance, while gross margin of 9.3% was at our midpoint. Selling and administrative expense of $39.3 million was above our guidance, primarily due to higher variable incentive compensation expense. As a percentage of revenue, SG&A was 4.6%, sequentially improved by 20 basis points and consistent with our expectations. Operating margin of 4.7% was at the midpoint of our guidance and within our target operating margin range. Included in this quarter's operating margin was approximately 60 basis points of stock-based compensation expense. Nonoperating expenses of $5.7 million were slightly above our guidance as a result of foreign exchange losses. Our GAAP effective tax rate for the fiscal first quarter was 10%, which included a net benefit of $800,000 related to special tax items recorded during the quarter. Excluding these items, our non-GAAP effective tax rate was 12%, slightly favorable to our guidance range of 13% to 15%. GAAP diluted EPS of $1.03 included $0.03 per share related to the special tax items. Excluding these items, non-GAAP diluted EPS of $1 was above the top end of our guidance primarily due to the strong revenue results. Turning now to the balance sheet and cash flow on Slide 14. During the quarter, we purchased approximately 91,000 shares of our stock for $6.3 million at an average price of $69.82 per share. At the end of the fiscal first quarter, we had approximately $40 million remaining under the authorization. For the fiscal first quarter, we were pleased with our free cash flow results. We generated $75 million in cash from operations and spent $14 million on capital expenditures, resulting in free cash flow of $61 million. We ended the quarter with a strong balance sheet. Cash of $255 million was sequentially higher by $29 million. We also reduced debt under our revolving credit facility by $33 million. Both improvements were primarily driven by strong cash flow generation. At the beginning of the quarter, we adopted the new accounting standard for leases. The balance sheet impact from adoption was a net addition of $46 million for leased assets and $47 million for leased liabilities. In calculating our return on invested capital, we are now including the lease liability within average invested capital. The impact from this inclusion is a detriment to ROIC of approximately 35 basis points. Despite this detriment, we were very pleased to deliver a 160 basis point improvement to our return on invested capital this quarter compared to our results in fiscal 2019. Cash cycle at the end of the first quarter was 71 days, a 9-day improvement from the fiscal fourth quarter. Over the past 2 quarters, we have improved our cash cycle by 18 days. Please turn to Slide 15 for details on our cash cycle. The 9-day sequential improvement was driven by a reduction to our receivable days and an increase to our payable days, each improved by 6 days. For receivable days, we experienced a better balance of shipments throughout the quarter compared to last quarter where shipments were weighted more towards the third month. Also, with the quarter ending January 4, we have the opportunity for additional collections from customers with a period close of December 31. For payable days, we experienced a return to more normalized procurement activity. Prior to the fiscal first quarter, we had a pullback in purchasing in order to improve our inventory management. We have now worked through that impact. As Todd has already provided the revenue and EPS guidance for the fiscal second quarter, I'll review some additional details, which are summarized on Slide 16. Fiscal second quarter gross margin is expected to be in the range of 8.8% to 9.2%. At the midpoint of this guidance, gross margin would be approximately 30 basis points lower than the fiscal first quarter. Todd mentioned the 50 basis point impact from seasonal compensation cost increases. Of this total, 40 basis points will impact gross margin. We also expect an impact on gross margin due to program pauses in engineering services. A portion of these impacts is anticipated to be offset by lower Healthcare costs in the second quarter compared to the fiscal first quarter. For the fiscal second quarter, we expect SG&A expense in the range of $38 million to $39 million. At the midpoint of our revenue guidance, anticipated SG&A would be 4.75% of revenue, sequentially up 15 basis points, primarily due to the seasonal compensation headwinds. Fiscal second quarter operating margin is expected to be in the range of 4% to 4.5%, which includes 80 basis points of stock-based compensation expense. The operating margin guidance is exclusive of any restructuring charges related to the strategic reposition of our Boulder Design Center. At this point, we are still formulating the details and overall charges associated with the plan. A few other notes for the fiscal second quarter: depreciation and amortization expense is expected to be approximately $15 million, slightly higher than the fiscal first quarter. Nonoperating expenses are expected to be in the range of $4.6 million to $5 million. At the midpoint of this guidance, these expenses would be sequentially lower by $900,000, primarily due to the absence of foreign exchange losses, which were experienced during the fiscal first quarter. For the fiscal second quarter, we estimate an effective tax rate of 13% to 15% and diluted shares outstanding of approximately 30 million shares. Our expectation for the balance sheet is for working capital dollars to increase as we ramp new programs during the quarter and begin procuring inventory later this quarter for the anticipated sequential increase in fiscal third quarter revenue. Based on our revenue forecast, we expect this level of working capital will result in cash cycle days of 75 to 79 days. For the fiscal second quarter, we expect free cash flow around breakeven as we ramp new programs and build inventory. We remain focused on sustaining inventory improvements and anticipate generating free cash flow in subsequent quarters. For the full year, we continue to expect free cash flow in excess of $100 million. Finally, our capital spending estimate for fiscal 2020 is expected to be in the range of $55 million to $70 million. With that, John, let's now open the call for questions.

[Operator Instructions]. And our first question is from Shawn Harrison from Longbow Research.

Just to say, I know it's a small piece of the mix and so it's probably not the biggest focus, but within the Communications, I think the old goal was to have that business flat potentially for the fiscal year. And with the underperformance last quarter and the decline this quarter, maybe if we could get into just what is the incremental weakness there? I think the thinking was that it had bottomed out, but it clearly hadn't. And maybe what could the back half look like? Is there further deceleration in that business?

This is Steve; I can handle that one. Looking at this quarter, I think, as you probably know, the MSOs are announcing their first quarter projections today and through the end of next week. And I think we'll get a lot more visibility into what their spending is going to be. So I think people are hesitant to really start building product in advance of those announcements. And so from an architectural standpoint, we do see distributed coming up a bit. We see a little bit of upside in more of the centralized architecture. And so I think people are really trying to figure out what is going to be the winner for the architecture as we go into fiscal '20. And I think that will dictate for us kind of what '20 looks like. As I look towards the back half of the year, we do see some strengthening. And even in Q3, the forecast now is basically holding with what we thought. But again, I think until we see what comes out from the MSOs and our spending patterns and our customers adjust their forecast, where we truly understand what the back half of '20 looks like.

One of the things I'd add, Shawn, is that our expectations for the longer term had been for comps to stay flat. I think for '20, we always expected it to be down because we face a really big headwind from some of the demand that's dropped from a significant customer within that space going into it. As Steve had mentioned, we have a couple of program ramps that could turn the trajectory of the revenue in a different direction in the back half of the year, but we'd still expect it to be a single-digit sector for us.

Okay. And then as a follow-up. I mean, Defense/Aerospace grew 40% in the December quarter; it looks like you have a really bullish outlook for '20 still. Are you seeing any impact from the production stoppage of the 737 Max? Or is it just that you've got so many diversified wins that that stoppage is not really impacting the business?

Yes, I think it's the latter, Shawn. I mean it's -- we have a very diversified portfolio within aerospace. I mean the indications on our 737 Max program is, there's been no impact as of yet. But even if there is, it will be negligible to our Aerospace and Defense revenue. You won't notice it.

All right. Great. Congrats on the results.

Thank you.

Thanks.

Our next question is from Matt Sheerin from Stifel.

Just a question regarding your operating margin guidance for the coming quarter and for the year. You're still looking at 4.7% to 5% range for the second half, but you did originally guide for the full year. Are you -- is that still something that you could achieve? Or is that, at this point really dependent on how the year shapes out?

Yes. I would say it's a bit dependent right now. I mean we see the back half of the year as being 4.7% to 5% with a pretty strong likelihood. But for the full year, I think it remains a little bit as to how we come through this quarter because this quarter is a bit more challenged than we had anticipated. But we should be right in that area for the full fiscal year.

And you're looking for pretty significant growth based on your wins in the second half wins from some of these sectors, and I know in the past, with some of these programs, there's cost related to that, which is always a little bit of a squeeze on margins. Is that factored into your guidance in terms of expectations because you have visibility on those ramps so you can manage those better?

It is. Yes, it is.

Okay. And then on the inventory side, pretty strong reduction. It sounds like you're going to start to build some inventory backup, are you seeing any signs of component constraints like you have in previous quarters? Or are you able to run relatively lean here?

Yes. Matt, this is Steve. We're not seeing the component constraints we saw in the past. I mean there's always an issue here and there that we'll continue to chase, but nothing compared to what it was in previous quarters.

Our next question is from Jim Ricchiuti from Needham & Company.

Just a question on some of the strength you're seeing in the semi-cap part of the industrial business. You seem to be suggesting that there may be some upside in that area of the business looking out over the balance of the year. Is that coming from multiple customers? And I assume that that is better margin business, is that correct?

So to answer the first part of your question, this is Steve. Yes, we see a potential for upside in the coming quarters. The question is -- and it's kind of how I stated it, is how much and when? I think, generally speaking, across all of the customers, they do expect to see upside in the coming quarters. It's really been hard to predict when that's going to hit. So obviously, this quarter was strong. That strength is continuing into this quarter. But what we see more in the back half of the year is what we're working through. So we're working very closely with customers to make sure that from a capacity standpoint and an inventory standpoint, we have the right things in place. And then in terms of margin profile, it varies by customer and by program. I mean it's in line with where Plexus' expectations are. So we'll...

Yes. Jim, this is Pat. I think when we see increased volumes from customers, we can gain some fixed cost leverage. But to Steve's point, it doesn't necessarily mean the margins are stronger by customer.

Got it. And just looking at the -- what you saw in the Healthcare/Life Science vertical. I'm just trying to understand, were there some -- was there some potential unexpected pull-ins of business that you might have been anticipating in the fiscal second quarter that benefited you in Q1?

Yes, we did see some pull-in that appears to be Q1 demand -- or first calendar quarter demand shifting into the fourth calendar quarter. So our Q2 shifting into Q1, we hadn't seen that. As we entered the quarter, it didn't appear that our customers were going to show any end of calendar year strength. But that changed over the course of the quarter, and we do expect it to have an impact on our current quarter.

And Todd, that was from multiple customers?

Multiple customers, yes.

15 of the top 20 had upside in the quarter.

Okay. Got it. And just -- I know you're not giving guidance -- specific guidance looking out to the fiscal second half, but it seems like there's the potential that your SG&A expense going forward is going to be at a slightly higher level? Is that also partly due to some of the mix changes you're seeing in the business?

Not necessarily, Jim. I think we can hold our SG&A to the levels they're at. This past quarter was higher because of higher incentive compensation, and that was a combination of the strong revenue and the return on invested capital. That's what was driving that higher. We do have the merit increases this quarter, but we typically work through those through productivity improvements. So I wouldn't expect it to be any higher than what we're looking at in Q2.

Okay. And then you alluded to some pause in the engineering program. So I wonder if you could just give a -- provide a little bit more color on that.

Yes. Well, we saw a couple of significant programs that paused, and I would call them for different reasons. And I wouldn't call them indications of any market softening; they're pausing because of issues around the customers, and one was with a more significant Healthcare OEM. And they're basically taking a closer look at their business case, balancing features versus development effort within that program. So that's caused them to step back for a bit. And others with a more early-stage customer that's really looking at their overall business model. So we think that there's a reasonable likelihood that both will go forward at some point; but right now, it's having a near-term impact for us.

Got it. And that early-stage customer, is that also Healthcare? Or is that in your -- one of your other sectors?

Yes. It is Healthcare. It is Healthcare.

Our next question is from Paul Coster from JP Morgan.

The manufacturing wins trend has been slightly down over the course of the last few quarters. You sound confident that it's going to rebound pretty quickly. And I'm just wondering what you think the underlying cause might be? Is it the trade uncertainty and disruptions to supply chains? Or is there some other reason for this recent trend and its pending reversal?

Yes. This is Steve. I'll handle that one. And actually, I think I misspoke in the beginning; I think I said our trailing four quarters were $450 million. It's actually $850 million. And so a quick correction on that one. But from a trend standpoint, I think one of the things that we're analyzing and looking at, as we look at the trailing four quarters, the Healthcare/Life Sciences and Aerospace and Defense sectors, those trailing four quarters -- the revenue levels for those quarters have been the highest they've been in the last couple of years. And so those programs are a bit smaller. But as we're trying to talk about here is the duration of the things that are significantly longer. And as we've basically deemphasized, and we see the Communications numbers coming down, those are historically higher numbers, but the program durations were much smaller. And so as we look forward, we're confident as we're growing in these diversified sectors, and Todd talked about that over 90% of our revenue is going to be in these diversified sectors, that we're generating the wins that we needed to continue to grow. And so I think one of the things we need to do is take a look at the metrics that we're using and make sure that now that we have this different portfolio, the size of the wins that we need, we believe, are supporting the business, and we'll have to make sure that our metrics are measuring the right thing.

Makes sense. You said 15 of the 20 Healthcare/Life Sciences customers pulled forward. Is there an underlying trend to explain that?

From my perspective, if you looked at the beginning of the quarter, we actually talked about the fact that we had historically in the past seen some seasonal upside in our fiscal Q1 related with the year-end demand. Our customers have not forecasted that as significant as they had in the past. And so we didn't know, quite frankly, if there was going to be softer demand in the Q1 -- in our Q1. But as we came through the quarter, we realized that that demand was really there and customers needed to pull it in, and so we did that for them. So I don't know there's much more we can read into it. I think the demand was strong at the year-end. Our customers didn't anticipate it. We reacted to it. And again, I think as we look at the forecast going into Q3, we think it's going to rebound back to a normal level. So we do see it as just a one or two quarter kind of fluctuation.

Last question is, so we're seeing a number of companies in this space following your script a bit, which is to deemphasize the short product cycle business, the volatile business and focus on these long product cycle verticals. And also, we're seeing some pricing discipline. Do you concur that there is sort of rational pricing happening in your industry at the moment? And how does that play out over the course of time?

Yes. From our perspective, there is rational pricing in the industry right now. From a competitive standpoint, though, we don't see things as being significantly different. I mean, it's always been competitive in our spaces. We've always, kind of, competed with the same people. That looks rather similar, but the pricing situation is, I would call it decent right now. So that's certainly a positive for all of us, I think, if we have good pricing discipline and drive to get value out of the services that we're providing.

Yes. And Paul, in some of these complex sectors that we operate within, there are higher working capital requirements. And so we've got to make sure the margins support that higher working capital. And I think our competitors are thinking the same and focusing on the return on invested capital side and ensuring those margins are high enough.

Our next question is from Anja Soderstrom from Sidoti.

Congratulations on the great quarter. And a lot of good questions asked already. I just wanted to follow up on, sort of, the contract wins. How can you bucket that from how much you are winning from existing customers versus winning -- transferring customers from in-house production? And maybe also, how you are comparing to peers?

So if I understood your question correctly, as we look at our wins in our funnel, we traditionally fall from a 60, 70 customer to a 30, 40 target split, both in wins as well as the funnel, and our focus varies by sector. For example, in our Healthcare/Life Sciences sector, we believe the number of logos and the customers that we have, there's a lot of opportunity to continue to harvest from them and support the growth that we need. Again, we're always looking at adding new customers. But again, they believe they have a strong customer base. As we looked at Industrial/Commercial, through fiscal 2019, one of the things we recognize is that we needed to add new customers to the portfolio. And so they focused -- that sector focused heavily on doing that and made great progress doing it. And so we do look at it by sector, but we think that roughly 70-30, 60-40 split from customers target as a very healthy path forward with us. Obviously, growing with customers is much easier. They ramp quicker than it does with targets. So we like that mix.

Okay. And also, you mentioned that you're moving the -- shifting into the 90% -- over 90% of your revenue in the Healthcare/Life Sciences and Aerospace and Defense and Industrial and Commercial. So -- and their life cycles there are much longer. Can you just remind us how those compare to the Communications? And how much shorter are the Communications?

Yes, sure. We tend to think of the Communications as being about a 3- to 5-year life cycle on programs. And whereas we look at Aerospace and Defense being in the mid- to mid-teens to even 20-year life cycle, and Healthcare and Industrial tending to be closer to a 10-year life cycle. So it's quite a difference in when you're providing solid execution, maintaining the business in the amount of churn that's in the portfolio and the amount of business that you need to win.

Okay. That was helpful. And also, lastly, what are you going to do with all the cash?

Good question. So we'll continue to buyback. We expect to execute that remaining portion of the buyback this year. And we are paying down some of our debt, and we'll continue to do those two things and then reevaluate. We continue to see this level of free cash flow moving forward. We'll look at our alternatives around a future buyback or consider the merits of a dividend, too.

And we have a follow-up question from Jim Ricchiuti from Needham & Company.

The repositioning of the Boulder Design Center at Boise. I assume that -- is that something that has been under consideration in the works for a bit?

It's been under consideration for a bit because we saw the advantages strategically of having an Aerospace and Defense center of excellence, as we see Aerospace and Defense as a great growth opportunity for our Engineering Solutions organization, and co-locating those two facilities made a lot of sense strategically. But really, the pauses in the engineering programs, I guess, were the impetus to be able to move forward with it. So what we had considered, it, it's a bit I'd call it -- it's taking -- or looking at the situation that we have in front of us and addressing it.

We have started our Boulder Design Center before our Boise operations. And if you had done it in reverse, you would do exactly what we're doing now, which having that center of excellence with the co-location and the full value stream is a significantly bigger value-add for our customers. And so as Todd said, taking advantage of the situation and making a better long-term strategic alignment is the right way to go for us.

And we have no further questions at this time. I'll now turn it back over to CEO, Todd Kelsey, for closing remarks.

All right. Thank you, John, and I just wanted to close briefly by thanking everyone who joined our call today. We appreciate your support. We appreciate your interest in Plexus.

And thank you, ladies and gentlemen. That concludes today's conference. Thank you for participating, and you may now disconnect.